Advancing Next-Generation NK Platforms through Antibody-Guided CAR-like NK Cells

• Showcasing a CAR-like NK platform that achieves targeted cytotoxicity via monoclonal antibody attachment, eliminating the need for genetic modification
• Presenting preclinical data validating the platform’s potent CD16-mediated activity

New Data

Speakers:

Martin Villalba

Co-Founder & Chief Scientific Officer

Inserm Lille Neuroscience & Cognition research centre